News · 26 weeks74+433%
2026-03-012026-08-23
Mix2890d
- Insider11(39%)
- Other8(29%)
- SEC Filings6(21%)
- Analyst1(4%)
- Earnings1(4%)
- Offering1(4%)
Latest news
25 items- SECSEC Form 144 filed by Caris Life Sciences Inc.144 - Caris Life Sciences, Inc. (0002019410) (Subject)
- INSIDERDirector Castleman Peter M was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Phillips T Danny was granted 13,192 shares, increasing direct ownership by 11% to 133,060 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Minor Lloyd was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Gilliam Joseph E was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Fredrickson David Paul was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Vacirca Jeff L was granted 13,192 shares, increasing direct ownership by 27% to 62,863 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Johansen Laura I was granted 13,192 shares, increasing direct ownership by 4% to 343,897 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Halbert Jon was granted 13,192 shares, increasing direct ownership by 11% to 131,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECSEC Form 144 filed by Caris Life Sciences Inc.144 - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECSEC Form 10-Q filed by Caris Life Sciences Inc.10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceRevenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology testsRaises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsReported total re
- SECSEC Form 144 filed by Caris Life Sciences Inc.144 - Caris Life Sciences, Inc. (0002019410) (Subject)
- PRCaris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, August 5, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qsA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About
- PRCaris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC TestingIRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology fo
- INSIDERDirector Halbert Jon bought $990,080 worth of shares (68,000 units at $14.56) (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- PRCaris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood TestUltra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologiesIRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra
- SECSEC Form CERT filed by Caris Life Sciences Inc.CERT - Caris Life Sciences, Inc. (0002019410) (Filer)
- SECSEC Form 8-A12B filed by Caris Life Sciences Inc.8-A12B - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Announces Dual Listing on NYSE TexasIRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market."Establishing a dual listing on NYSE Texas re
- PRCaris Life Sciences Announces Share Repurchase ProgramIRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as ame
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
CAI FAQ
7 questionsWhat does Caris Life Sciences Inc. do?
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost...Where does CAI stock trade?
Caris Life Sciences Inc. (CAI) is listed on NYSE.What sector and industry is CAI in?
Caris Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Caris Life Sciences Inc. go public?
Caris Life Sciences Inc. (CAI) completed its IPO in 2025.What are analysts saying about CAI?
Caris Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets range from $2100.00 to $3100.00.What companies are similar to CAI?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CAI side-by-side with any of them on Quantisnow.How can I track CAI on Quantisnow?
Quantisnow aggregates Caris Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAI to receive live email and push alerts on every new disclosure.